2023
Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature
Soto F, Torre-Sada L, Mott F, Kim S, Nurieva R, Nagarajan P, Guo M, Shannon V, Faiz S, Casal R, Altan M, Lin J, Sheshadri A. Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature. Journal Of Immunotherapy And Precision Oncology 2023, 6: 111-116. PMID: 37214206, PMCID: PMC10195014, DOI: 10.36401/jipo-22-30.Peer-Reviewed Original ResearchImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyInhibitor therapyPulmonary toxicityEosinophilic asthmaAirway diseaseImmune related adverse eventsPD-1 inhibitor pembrolizumabSevere eosinophilic asthmaRelated adverse eventsICI therapyInhibitor pembrolizumabPD-1Benign courseTreatment cessationFatal complicationCase reportAdverse eventsSarcoidosisTherapyPneumonitisAirwayPatientsToxicityAsthma
2017
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
Kim S, Tayar J, Trinh V, Suarez-Almazor M, Garcia S, Hwu P, Johnson D, Uemura M, Diab A. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals Of The Rheumatic Diseases 2017, 76: 2061. PMID: 28830882, DOI: 10.1136/annrheumdis-2017-211560.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsCheckpoint inhibitorsReceptor antibodiesAssociated with immune-related adverse eventsMild immune-related adverse eventsEffective alternative to corticosteroidsEfficacy of ICI therapyICI-induced inflammatory arthritisImmune checkpoint inhibitor therapyAnti-IL-6 receptor antibodyAlternative to corticosteroidsTreated with corticosteroidsTreated with tocilizumabTumor necrosis factor-aImmune dampening effectsInflammatory side effectsAlternative therapeutic strategiesFood and Drug AdministrationTreatment of rheumatoid arthritisJuvenile idiopathic arthritisAntitumour responseICI therapyTNFa inhibitorsCheckpoint inhibition